BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction (lines 7-19; page 5): for the sake of clarity, the sentence should be rephrased as "....have recommended emesis prophylaxis using a three-drug regimen ....in patients receiving carboplatin-based chemotherapy." Introduction (lines 43-46; page 5): this statement is entirely debatable as the use of an antiemetic must be based on the expected risk of CINV for a patient and not only on the cost of the drug. In light of this, if thoracic cancer patients treated with carboplatin have an inherent risk of CINV that can make the use of an NK-1RA unnecessary, the authors should explain the reason why they are evaluating the addition of olanzapine in this setting. This is a very important issue as currently available evidence on olanzapine supports the use of olanzapine instead of an NK-1RA in the management of CINV (see reference 2). Introduction (lines 4-10; page 6): the sentence should be rephrased as it is not correct. The Navari study was a superiority study that could not demonstrate equivalence between the two treatment arms (see reference 10). Since in the Navari study palonosetron and dexamethasone were administered only on day 1 in patients treated with HEC regimens and receiving olanzapine on day 1 through 4, the authors should explain the clinical rationale for using granisetron with additional doses of dexamethasone. It is well known that granisetron plus dexamethasone is significantly less effective than palonosetron plus dexamethasone in the setting of CINV caused by HEC (Saito M et al. Lancet Oncol 2009; 10:115-124) . There also randomised data demonstrating that palonosetron plus 1-day dexamethasone is not inferior to palonosetron plus 3-day dexamethasone in female patients receiving AC-based HEC (Aapro M et al. Ann Oncol 2010; 21:1083 -1088 . Last but not least, in light of the use of immunotherapy in combination with chemotherapy for lung cancer, it is extremely important to reduce the total dose of dexamethasone administered during each treatment cycle. The authors should comment on these specific issues that can impact the clinical relevance of the study findings to the management of CINV in the setting of thoracic cancer (namely lung cancer). Introduction (lines 10-19; page 6): the sentence should be rephrased as references 11-14 cited in the text do not refer to European studies. Introduction (lines 34-46; page 6): although the cost of drugs is an important aspect in the presence of increasingly limited health budgets, it cannot be the only rationale for this study. See the above comments. End points (lines 58 on page 7; lines 4-7 on page 8): the definition of complete control is not correct. Complete control is defined as no emetic episodes, no rescue medication use, and no more than mild nausea. End points (lines 16-19; page 8): it seems to be questionable assessment of TTF in this single-arm study. End points (lines 22-26; page 8): I do not understand the meaning of this sentence. The authors should specify in the text what they intend to evaluate and the tools used for evaluation. Exclusion criteria (line 19; page 10): the statement "patients deemed inappropriate for the study by the investigator" should be better clarified. 
VERSION 1 -AUTHOR RESPONSE
Reviewer #1
I assume this is a description of the proposed study with no results at this point?
=> As you pointed out, our manuscript is study protocol. This study is currently ongoing. There are no results at this time. Therefore, the following sentences were added (from line 4 to line 8 of page 14 in the revised version):
Trial status
February 2018: protocol approval by the Ethics Committee.
February 2018: Start of inclusion.
December 2019: End of inclusion.
We will submit the manuscript during the first half of 2020.
Reviewer #2
Introduction (lines 55-58 on page 4; line 4 on page 5): the sentence should be rephrased as it is not correct. MASCC classifies carboplatin as moderately emetogenic with an acute emetic risk at the upper limit of the MEC category regardless of the carboplatin dose (see reference 2) . ASCO =>We summarized the guidelines for carboplatin in the table below. Based on this table and your suggestions, the sentences were modified as followed (from line 8 of page4 to line 1 of page 9 in the revised version):
"Carboplatin (CBDCA) administered to achieve an area under the blood concentration-time curve (AUC) of ≥4 mg/mL/min is ranked as the highest risk drug among the moderately emetogenic chemotherapy (MEC) agents and/or the highly emetogenic chemotherapy (HEC). =>Thank you for your suggestion. With your suggestions and the above changes, the sentences were modified as followed (from line 1 to line 7 of page 5 in the revised version): Introduction (lines 43-46; page 5): this statement is entirely debatable as the use of an antiemetic must be based on the expected risk of CINV for a patient and not only on the cost of the drug. In light of this, if thoracic cancer patients treated with carboplatin have an inherent risk of CINV that can make the use of an NK-1RA unnecessary, the authors should explain the reason why they are evaluating the addition of olanzapine in this setting. This is a very important issue as currently available evidence on olanzapine supports the use of olanzapine instead of an NK-1RA in the management of CINV (see reference 2).
=>As you pointed out, the cost aspect is not the only problem for prophylaxis of CINV. For NK1RA, there are problems with drug-drug interaction, and some cases. It is difficult to use. Therefore, we believe that the development of antiemetic therapy without NK1RA is necessary.
The evidence for olanzapine is mainly for HEC. As the effects of NK1RA differ among MEC agents (CBDCA alone is a strong recommendation for NK1RA use), we consider that the effect of olanzapine is different for each agent. Therefore, we believe that the effects of olanzapine should also be considered for each emetic risk, or each agent. For those reasons, the following sentences were added (from line 17 of page 5 to line 1 of page 6 in the revised version):
Furthermore, because of the inhibition of cytochrome P450 3A4, clinically significant pharmacokinetic interactions of apreitant (APR) and fosaprepitant have been reported not only general agents but also chemotherapy agents [9] . Therefore, the development of antiemetic therapy without NK1RA is beneficial in complicated cancer chemotherapy.
Introduction (lines 4-10; page 6): the sentence should be rephrased as it is not correct. The Navari study was a superiority study that could not demonstrate equivalence between the two treatment arms (see reference 10).
=>As you pointed out, the Navari study could not demonstrate that olanzapine regimen is superior to aprepitant regimen. Therefore, the sentences were revised as follows (from line 5 to line 11 of page 6 in the revised version):
"Navari et al. reported that 10mg OLZ combined with palonosetron (PALO) and DEX has an equivalent antiemetic effect to an antiemetic regimen consisting of PALO, DEX, and aprepitant (APR), in CR rate, and excellent in control of nausea in highly emetogenic chemotherapy (HEC)" ------------------>" Navari et al. performed a phase III trial to confirm the superiority of 10mg OLZ combined with palonosetron (PALO) and DEX to an antiemetic regimen consisting of PALO, DEX, and APR in highly emetogenic chemotherapy (HEC). The study could not demonstrate that the OLZ regimen is superior to the APR regimen. However, the CR rates for the acute, delayed, and overall period were not significantly different between the OLZ regimen and the APR regimen. On the other hand, the OLZ regimen showed excellent control of nausea in the delayed and overall period"
Since in the Navari study palonosetron and dexamethasone were administered only on day 1 in patients treated with HEC regimens and receiving olanzapine on day 1 through 4, the authors should explain the clinical rationale for using granisetron with additional doses of dexamethasone. It is well known that granisetron plus dexamethasone is significantly less effective than palonosetron plus dexamethasone in the setting of CINV caused by HEC (Saito M et al. Lancet Oncol 2009; 10:115-124) . There also randomised data demonstrating that palonosetron plus 1-day dexamethasone is not inferior to palonosetron plus 3-day dexamethasone in female patients receiving AC-based HEC (Aapro M et al. Ann Oncol 2010; 21:1083 -1088 . Last but not least, in light of the use of immunotherapy in combination with chemotherapy for lung cancer, it is extremely important to reduce the total dose of dexamethasone administered during each treatment cycle. The authors should comment on these specific issues that can impact the clinical relevance of the study findings to the management of CINV in the setting of thoracic cancer (namely lung cancer).
=>In recent years, immune checkpoint inhibitor (ICI) in combination with chemotherapy is available in clinical setting for lung cancer. Arbour et al. reported that baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcomes in patients with non-small-cell lung cancer who were treated with ICI (J Clin Oncol. 2018; 36:2872 -2878 . Therefore, there is a concern that DEX as emesis prophylaxis may affect the effects of ICI combination chemotherapy.
The noninferiority of DEX sparing on day 2 and 3, combined with PALO has been demonstrated for MEC in randomized control trials (Aapro et al. Ann Oncol 2010; 21:1083 -1088 , Celio et al. Support Care Cancer. 2011 19:1217 -25, Komatsu et al. Cancer Sci. 2015 106:891-5) . Therefore, to use PALO can reduce corticosteroid.
Among the ICI combination therapies, the pembrolizumab combined with CBDCA and pemetrexed is one of the most used regimens for advanced non-small-cell lung cancer. In the KEYNOTE-189 trial that proved the effectiveness of this regimen, for prophylaxis of cutaneous reaction, the administration of DEX 8 mg per day for 2 days besides DEX of day 1 used for antiemetic therapy had been regulated by the protocol (Gandhi et al. N Engl J Med. 2018; 378:2078 -2092 . In consideration of these, DEX is administered for 3 days in our protocol.
About 5HT3RA, the effectiveness of olanzapine combination has been revealed in both first and second generation (first generation 5HT3RA: Wang et al. Cell Biochem Biophys 2015; 72:471-3, Navari et al. N Engl J Med 14; 375:134-42, Tan et al. J Exp Clin Cancer Res. 2009; 28:131) . Therefore, the first-generation 5HT3RA is administered in our protocol.
For those reasons, the following sentences were added (from line 6 of page 7 to line 1 of page 8 in the revised version):
In recent years, immune checkpoint inhibitor (ICI) in combination with chemotherapy is available in clinical settings for lung cancer. Arbour et al. reported that baseline corticosteroid use was associated with poorer outcomes in patients who were treated with ICI [19] . Therefore, there is a concern that DEX as emesis prophylaxis may affect the effects of ICI combination chemotherapy. The noninferiority of DEX sparing on day 2 and 3, combined with PALO has been demonstrated for MEC in randomized control trials [20] [21] [22] . Therefore, to use PALO can reduce corticosteroid. Among the ICI combination therapies, the pembrolizumab combined with CBDCA and pemetrexed is one of the most often used regimens for advanced non-small-cell lung cancer. In the KEYNOTE-189 trial that proved the effectiveness of this regimen, for prophylaxis of cutaneous reaction, the administration of DEX 8 mg per day for 2 days besides DEX of day 1 used for antiemetic therapy had been regulated by the protocol [23] . Therefore, we plan to administer DEX for 3 days.
The efficacy of OLZ has been demonstrated in both combinations with the first and second generation 5HT3RA in HEC [11] [12] [13] [14] [15] [16] [17] [18] 24] . Therefore, granisetron (GRN) was chosen as 5HT3RA in the study.
Introduction (lines 10-19; page 6): the sentence should be rephrased as references 11-14 cited in the text do not refer to European studies.
=>The sentence was corrected, as you suggested (from line 12 of page 6 in the revised version):
"in Europe and the United States," ------------------>" in the United States and Asia,"
Introduction (lines 34-46; page 6): although the cost of drugs is an important aspect in the presence of increasingly limited health budgets, it cannot be the only rationale for this study. See the above comments.
=> As you pointed out, the cost aspect is not the only problem for prophylaxis of CINV. Therefore, we made the revision above.
End points (lines 58 on page 7; lines 4-7 on page 8): the definition of complete control is not correct. Complete control is defined as no emetic episodes, no rescue medication use, and no more than mild nausea.
=>The definition of complete control was corrected, as you suggested (from line 6 to line 8 of page 9 in the revised version):
"complete control rate (defined as the absence of nausea and emetic episodes and no use of rescue medication during the overall assessment period)." ------------------>" complete control rate defined as no significant nausea, no emetic episodes, and no use of rescue medication for the acute, delayed, and overall assessment periods."
End points (lines 16-19; page 8): it seems to be questionable assessment of TTF in this single-arm study.
=> We deeply appreciate your kind advice. Our research has already been started. Although this is a single arm study, TTF will be evaluated as an exploratory indicator that is used to reveal when a patient will become non-CR.
End points (lines 22-26; page 8): I do not understand the meaning of this sentence. The authors should specify in the text what they intend to evaluate and the tools used for evaluation.
=>Thank you for your suggestion. The sentences were modified as followed (from line 13 to line 15 of page 9 in the revised version):
"Severity has been classified into a four-grade categorical scale, including nausea, anorexia, sleepiness, and the impact on life. Patient satisfaction with antiemetic therapy." --------------------------->" The levels of nausea, anorexia, sleepiness, impact on life severity, and patient satisfaction with antiemetic therapy are also classified using a four-grade categorical scale. These data are collected from patient diaries."
Exclusion criteria (line 19; page 10): the statement "patients deemed inappropriate for the study by the investigator" should be better clarified.
=>Thank you for your suggestion. The following sentences were added (from line 9 to line 10 of page 11 in the revised version):
(From daily behavior, patients who may not be able to keep medication adherence and/or fulfill patient diary etc.) Table 1 is not cited in the text.
=>According to your comment, we inserted the following sentences (from line 16 of page 11 in the revised version):
